Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Pharmaceutical Obtains Approval for Additional Indication for Anticancer Agent Herceptin
November 28, 2011
- Additional Indication of Solar Keratosis Approved for Mochida Pharmaceutical's Beselna Cream
November 28, 2011
- 26 Major JPMA Member Companies Report Declines in Sales, Profits, with 8.8% Drop in Overseas Sales
November 25, 2011
- Takeda Files NDA for Fixed-Dose Combination of DPP-4 Alogliptin, Metformin with US FDA
November 25, 2011
- MTPC, Novartis Pharma: Imusera 0.5 mg/Gilenya 0.5 mg for Treatment of MS
November 25, 2011
- Asahi Kasei: Teribone SC Injection 56.5 µg for Treatment of Osteoporosis
November 25, 2011
- MTPC: Telavic Tablets 250 mg to Treat Chronic Hepatitis C
November 25, 2011
- 25 Leading Drug Makers Report Overall Decline in Sales, Profits in 1st Half
November 24, 2011
- Astellas President Hatanaka Highly Expects “Bio-Lead Project
November 22, 2011
- Sakai Chemical to Make Kaigen Wholly Owned Subsidiary
November 22, 2011
- ASKA Aims at ¥20 Billion Sales in Generics Business: President Yamaguchi
November 22, 2011
- Ajinomoto, Interprotein Sign Joint R&D Agreement for PPI Inhibitors
November 22, 2011
- Sanofi, Nichi-Iko to Copromote Latter's Generic Drugs
November 22, 2011
- US FDA Accepts NDA for Once-monthly Depot Formulation of Abilify
November 22, 2011
- US Court Issues Amended Ruling in Litigation Between Asahi Kasei Pharma, Actelion
November 22, 2011
- OncoTherapy to File for Therapeutic Pancreatic Cancer Vaccine in Sept. 2012
November 22, 2011
- Sawai, Nichi-Iko Boost Inventory Ahead of Expected PAL Amendment
November 21, 2011
- FDA Extends Action Date for Takeda’s Alogliptin for 3 Months
November 21, 2011
- Eli Lilly Japan to Provide Alimta to Research for Free
November 21, 2011
- Novartis, Eisai to Copromote Onbrez
November 21, 2011
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…